NDC 64239-001 - PerioChip
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 64239-001
- Manufacturer
- Adrian Pharmaceuticals, LLC | Dexcel Ltd. | Dexcel Pharma Technologies Ltd.
- Effective date
- 2010-03-05
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PerioChip, 2.5 mg (Chlorhexidine Gluconate) | Adrian Pharmaceuticals, LLC | Dexcel Ltd. | Dexcel Pharma Technologies Ltd. | 2010-03-05 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| Chlorhexidine Gluconate | ACTIVE INGREDIENT | MOR84MUD8E | PERIOCHIP (CHLORHEXIDINE GLUCONATE) INSERT, EXTENDED RELEASE [ADRIAN PHARMACEUTICALS, LLC] | 1 | |
| Chlorhexidine | ACTIVE MOIETY | R4KO0DY52L | PERIOCHIP (CHLORHEXIDINE GLUCONATE) INSERT, EXTENDED RELEASE [ADRIAN PHARMACEUTICALS, LLC] | 1 | |
| Gelatin | INACTIVE INGREDIENT | 2G86QN327L | PERIOCHIP (CHLORHEXIDINE GLUCONATE) INSERT, EXTENDED RELEASE [ADRIAN PHARMACEUTICALS, LLC] | 1 | |
| Glutaral | INACTIVE INGREDIENT | T3C89M417N | PERIOCHIP (CHLORHEXIDINE GLUCONATE) INSERT, EXTENDED RELEASE [ADRIAN PHARMACEUTICALS, LLC] | 1 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | PERIOCHIP (CHLORHEXIDINE GLUCONATE) INSERT, EXTENDED RELEASE [ADRIAN PHARMACEUTICALS, LLC] | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | PERIOCHIP (CHLORHEXIDINE GLUCONATE) INSERT, EXTENDED RELEASE [ADRIAN PHARMACEUTICALS, LLC] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.